52-week, randomized, double-blind, double-dummy, parallel-group, multicenter, non-inferiority study to assess exacerbation rate, additional measures of asthma control, and participant safety
COMMERCIAL CLINICAL TRIAL
Clinical trial information
- Promoter: GLAXOSMITHKLINE RESEARCH DEVELOPMENT LTD
- Phase: III
- Execution start: 20/07/2021
- End of execution: 30/12/2023
- IP: CONCEPTION MORALES GARCIA